POPULARITY
19 episodes with randomized clinical trial
19 episodes with randomized clinical trial
10 episodes with randomized clinical trial
4 episodes with randomized clinical trial
2 episodes with randomized clinical trial
3 episodes with randomized clinical trial
2 episodes with randomized clinical trial
3 episodes with randomized clinical trial
2 episodes with randomized clinical trial
Interview with Michael McDermott, MBChB, author of CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial, and Pamela S. Douglas, MD, author of The Last Mile in Prevention—Can Coronary CT Angiography Help? Hosted by Ann Marie Navar, MD, PhD. Related Content: CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy The Last Mile in Prevention—Can Coronary CT Angiography Help?
Interview with Michael McDermott, MBChB, author of CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial, and Pamela S. Douglas, MD, author of The Last Mile in Prevention—Can Coronary CT Angiography Help? Hosted by Ann Marie Navar, MD, PhD. Related Content: CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy The Last Mile in Prevention—Can Coronary CT Angiography Help?
This is a capstone presentation from Chief Resident of Mayo Clinic Emergency Medicine, Dr. Taylor Christian. Teaser: Can we fulfill our oath to “do no harm” if we ignore the harm of racial injustice in medicine? Understanding the historical roots and persistent impact of medical racism isn't just informative; it is a call to action. This presentation is an opportunity to learn, reflect, and act to become better advocates. CONTACTS X - @AlwaysOnEM; @VenkBellamkonda; @TayMChristian YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch; @drtaylormonet Email - AlwaysOnEM@gmail.com REFERENCES & LINKS Meisel ZF, Shofer FS, Dolan AR, Goldberg E, Cannuscio CC, Rhodes KV, Perrone J, Hess EP, Rogers M, Bellamkonda V, Bell J, Zyla M, Becker L, McCollum S, Schapira M. Comparing Three Ways to Help Patients with Acute Pain Learn about Opioid Risks — The Life STORRIED Study [Internet]. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 Oct. PMID: 39383261. Engel-Rebitzer E, Dolan AR, Aronowitz SV, Shofer FS, Nguemeni Tiako MJ, Schapira MM, Perrone J, Hess EP, Rhodes KV, Bellamkonda VR, Cannuscio CC, Goldberg E, Bell J, Rodgers MA, Zyla M, Becker LB, McCollum S, Meisel ZF. Patient Preference and Risk Assessment in Opioid Prescribing Disparities: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021 Jul 1;4(7):e2118801. doi: 10.1001/jamanetworkopen.2021.18801. PMID: 34323984; PMCID: PMC8322998. Racic M, Roche-Miranda MI, Fatahi G. Twelve tips for implementing and teaching anti-racism curriculum in medical education. Med Teach. 2023 Aug;45(8):816-821. doi: 10.1080/0142159X.2023.2206534. Epub 2023 May 3. PMID: 37134226. Sahai A, Corley AMS, Lipps L, Lawton R, DeBlasio D, Klein M. A Locally-Focused Structural Racism Curriculum for Pediatric Primary Care Residents. Acad Pediatr. 2023 Nov-Dec;23(8):1510-1512. doi: 10.1016/j.acap.2023.06.012. Epub 2023 Jun 9. PMID: 37302703. Carrera D, Tejeda C, Kakani P, Napolitano J. Addressing Racism in Medical Education: A Longitudinal Antiracism Discussion Curriculum for Medical Students. Med Sci Educ. 2023 Apr 28;33(3):639-643. doi: 10.1007/s40670-023-01788-x. PMID: 37501797; PMCID: PMC10368613. Seegmiller Renner AM, Gross JR, Laughlin-Tommaso SK. Paving a Path to Inclusion, Diversity, Anti-Racism, and Equity: A Curriculum Roadmap. Mayo Clin Proc. 2023 Dec;98(12):1755-1762. doi: 10.1016/j.mayocp.2023.08.026. PMID: 38043992.
Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial Journal of the American Medical Association This 12-week randomized clinical trial in 261 treatment-seeking youth aged 16 to 25 years assessed if varenicline, when added to brief, remotely delivered behavioral support, was efficacious and well tolerated for nicotine vaping cessation in youth. Researchers found that continuous abstinence rates were higher in the varenicline group than in the placebo group in the last month of treatment (51% vs 14%) and at 6-month follow-up (28% vs 7%). Treatment-emergent adverse events did not differ significantly between groups. Varenicline, when added to brief cessation counseling, is well tolerated and promotes nicotine vaping cessation compared with placebo in youth with addiction to vaped nicotine. Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM
In this episode, Dr. Valentin Fuster dives into the complex and high-stakes world of cardiogenic shock, spotlighting new clinical trials, expert consensus guidance, and cutting-edge insights from machine learning. From evaluating the impact of intra-aortic balloon pumps to rethinking mechanical support strategies, the episode delivers a powerful update on one of cardiology's most urgent challenges.
Send us a textLung Recruitment Before Surfactant Administration in Extremely Preterm Neonates: 2-Year Follow-Up of a Randomized Clinical Trial.Gallini F, De Rose DU, Iuliano R, Romeo DM, Tana M, Paladini A, Fusco FP, Nobile S, Cota F, Tirone C, Aurilia C, Lio A, Esposito A, Costa S, D'Andrea V, Ventura ML, Carnielli V, Dani C, Mosca F, Fumagalli M, Scarpelli G, Giordano L, Fasolato V, Petrillo F, Betta P, Solinas A, Gitto E, Gargano G, Mescoli G, Martinelli S, Di Fabio S, Bernardo I, Tina LG, Staffler A, Stasi I, Mondello I, Scapillati E, Vedovato S, Maffei G, Bove A, Vitaliti M, Terrin G, Lago P, Gizzi C, Strozzi C, Villani PE, Berardi A, Cacace C, Bracaglia G, Pascucci E, Cools F, Pillow JJ, Polglase G, Pastorino R, van Kaam AH, Mercuri E, Orfeo L, Vento G; IN-REC-SUR-E Study Group; Malguzzi S, Rigotti C, Cecchi A, Nigro G, Costabile CD, Roma E, Sindico P, Venafra R, Mattia C, Conversano M, Ballardini E, Manganaro A, Balestri E, Gallo C, Catenazzi P, Astori MG, Maranella E, Grassia C, Maiolo K, Castellano D, Massenzi L, Chiodin E, Gallina MR, Consigli C, Sorrentino E, Bonato S, Mancini M, Perniola R, Giannuzzo S, Tranchina E, Cardilli V, Dito L, Regoli D, Tormena F, Battajon N, Arena R, Allais B, Guidotti I, Roversi F, Meli V, Tulino V, Casati A.JAMA Netw Open. 2024 Sep 3;7(9):e2435347. doi: 10.1001/jamanetworkopen.2024.35347.PMID: 39320892 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Send us a textEs geht mal wieder um Intensivmedizin, ganz konkret um den Einsatz von Sevofluran zur inhalativen Sedierung im ARDS:Jabaudon M, Quenot J, Badie J, et al. Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial. JAMA. Published online March 18, 2025. doi:10.1001/jama.2025.3169Im Studio mit dabei: Dr. Chiara Heim, wissenschaftliche Mitarbeiterin der Klinik für Anästhesiologie am UKHD
Send us a textWhole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.Faix RG, Laptook AR, Shankaran S, Eggleston B, Chowdhury D, Heyne RJ, Das A, Pedroza C, Tyson JE, Wusthoff C, Bonifacio SL, Sánchez PJ, Yoder BA, Laughon MM, Vasil DM, Van Meurs KP, Crawford MM, Higgins RD, Poindexter BB, Colaizy TT, Hamrick SEG, Chalak LF, Ohls RK, Hartley-McAndrew ME, Dysart K, D'Angio CT, Guillet R, Kicklighter SD, Carlo WA, Sokol GM, DeMauro SB, Hibbs AM, Cotten CM, Merhar SL, Bapat RV, Harmon HM, Sewell E, Winter S, Natarajan G, Mosquera R, Hintz SR, Maitre NL, Benninger KL, Peralta-Carcelen M, Hines AC, Duncan AF, Wilson-Costello DE, Trembath A, Malcolm WF, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA Pediatr. 2025 Feb 24:e246613. doi: 10.1001/jamapediatrics.2024.6613. Online ahead of print.PMID: 39992674As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
In this episode we discuss 4 more articles that changed our practice. Listen to us talk through real cases, what we used to do, and what we do now. Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. JAMA. 2024 May 28; 331(20):1722-1731. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 3;7(6):e2417377. Understanding the shared meaning of recovery from substance use disorders: New findings from the What is Recovery? Study. Substance Abuse: Research and Treatment, 17, 1–12. Long-term buprenorphine treatment for kratom use disorder: A case series. Substance Abuse, 2022. 43(1), 763–766. --- ASAM Advocacy Center — Thank you to the Pennsylvania Society of Addiction Medicine! --- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES. CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/ --- Original theme music: composed and performed by Benjamin Kennedy Audio editing: Michael Bonanno Executive producer: Dr. Patrick Beeman A podcast from Ars Longa Media --- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice. The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club Instagram: @AddictionMedJC Threads: @AddictionMedJC YouTube: addictionmedicinejournalclub Twitter/X: @AddictionMedJC Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-423 Overview: The use of electronic devices has increased across all ages, cultures, and socio-economic levels. Usage was also affected by the COVID-19 pandemic. There is a growing body of evidence that screen time can impact cognition and executive function in developing minds, and both the American Academy of Pediatrics (AAP) and the WHO have recommendations on screen time exposure for children. Join us as we discuss recent evidence looking at the impact of screentime on toddlers' cognition and executive function over time. Episode resource links: Fitzpatrick, C., Florit, E., Lemieux, A., Garon-Carrier, G, Mason, L. Associations between preschooler screentime trajectories and executive function. Academic Pediatrics, Volume 0, Issue 0, 102603. Schmidt-Persson J, Rasmussen MGB, Sørensen SO, et al. Screen Media Use and Mental Health of Children and Adolescents: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(7):e2419881. doi:10.1001/jamanetworkopen.2024.19881 AAP Screen Time Guidelines Schmidt-Persson J, Rasmussen MGB, Sørensen SO, et al. Screen Media Use and Mental Health of Children and Adolescents: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(7):e2419881. doi:10.1001/jamanetworkopen.2024.19881 Raj D, Ahmad N, Mohd Zulkefli NA, Lim PY. Stop and Play Digital Health Education Intervention for Reducing Excessive Screen Time Among Preschoolers From Low Socioeconomic Families: Cluster Randomized Controlled Trial. J Med Internet Res. 2023;25:e40955. Published 2023 May 4. doi:10.2196/40955 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-423 Overview: The use of electronic devices has increased across all ages, cultures, and socio-economic levels. Usage was also affected by the COVID-19 pandemic. There is a growing body of evidence that screen time can impact cognition and executive function in developing minds, and both the American Academy of Pediatrics (AAP) and the WHO have recommendations on screen time exposure for children. Join us as we discuss recent evidence looking at the impact of screentime on toddlers' cognition and executive function over time. Episode resource links: Fitzpatrick, C., Florit, E., Lemieux, A., Garon-Carrier, G, Mason, L. Associations between preschooler screentime trajectories and executive function. Academic Pediatrics, Volume 0, Issue 0, 102603. Schmidt-Persson J, Rasmussen MGB, Sørensen SO, et al. Screen Media Use and Mental Health of Children and Adolescents: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(7):e2419881. doi:10.1001/jamanetworkopen.2024.19881 AAP Screen Time Guidelines Schmidt-Persson J, Rasmussen MGB, Sørensen SO, et al. Screen Media Use and Mental Health of Children and Adolescents: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(7):e2419881. doi:10.1001/jamanetworkopen.2024.19881 Raj D, Ahmad N, Mohd Zulkefli NA, Lim PY. Stop and Play Digital Health Education Intervention for Reducing Excessive Screen Time Among Preschoolers From Low Socioeconomic Families: Cluster Randomized Controlled Trial. J Med Internet Res. 2023;25:e40955. Published 2023 May 4. doi:10.2196/40955 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com
Ivermectin, widely known as an antiparasitic medication, has been investigated for its potential anticancer properties in preclinical studies. Researchers have explored its effects on various cancer cell lines and its possible mechanisms of action. In this episode, Dr. Moss weighs in on this controversial topic, and let's us know where he feels the scientific research stands, and what the implications of the research mean for the future of cancer treatment.
Use the code KETOGIRL for 20% off your order of Spirulina Here A new study reveals a surprising truth: muscle mass and strength don't always improve the same way. While protein intake plays a key role in muscle growth, micronutrient deficiencies—especially in Vitamin D, B12, Magnesium, and Iron—can significantly impact strength gains. In this episode, I break down a new randomized clinical trial that studied older women at risk of sarcopenia and analyzed how different types of resistance training and dietary intake affected muscle function, body composition, and overall strength. What You'll Learn in This Episode: • The difference between muscle mass gains and strength gains and why they require different approaches • Which micronutrients are essential for building strength and muscle function • Why protein intake alone isn't enough and what you need to focus on instead • How to assess your own micronutrient levels for better performance and recovery as well as the top micronutrient rich foods to prioritize with a foods-first approach • Practical diet, supplement and training tips to maximize both muscle and strength If you want to build strength and muscle efficiently, or if you are health-conscious and looking to optimize your diet and training, this episode is packed with actionable insights. Mentioned in this episode: Nutritional intake as a determinant of high-speed resistance and multicomponent training efficacy on strength in older women at risk of sarcopenia. A Randomized Clinical Trial. Luis Polo-Ferre Visit Energybits.com (Use code KETOGIRL for 20% off your order) Get 10% off Bioptimizer's Magnesium Breakthrough with the code VANESSA HERE Get 20% off the New TONE LUX CONTOUR or the 2nd Generation Tone Device HERE with the code VANESSA Follow @ketogenicgirl for updates on the latest studies and strategies to optimize protein intake and metabolic health. Follow @optimalproteinpodcast on Instagram to see visuals and posts mentioned on this podcast. Link to join the facebook group for the podcast: https://www.facebook.com/groups/2017506024952802/ The content provided in this podcast is for informational purposes only and should not be construed as medical advice. Consult with a healthcare professional before making significant changes to your diet or exercise regimen.
Host Dr. Shannon Westin and guests Dr. Bill Aronson discuss the article "High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial" and how Omega-6 are predominant in the American diet while the study significantly lowered the intake of Omega- 6 fats. TRANSCRIPT Dr. Shannon Westin: Hello everyone and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts published in the Journal of Clinical Oncology. I'm your host, Dr. Shannon Westin, GYN Oncologist by trade and one of the grateful Social Media Editors of the JCO. And I am very excited to welcome a special guest today, Dr. William Aronson. He is professor of Urology in the UCLA Department of Urology, the Chief of Urology at Olive View UCLA Medical Center, and Chief of Urologic Oncology at the Veterans Administration West Los Angeles. Welcome, Dr. Aronson. Dr. William Aronson: Thank you, Shannon, and delighted to be here. Dr. Shannon Westin: We are so excited to have you discussing your manuscript, “High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial,” which was published in the Journal of Clinical Oncology on December 13, 2024. So let's get right to it. First of all, you know we have a very mixed audience, so can you just level set for us and speak about the population you studied in this important trial - that low risk, favorable, intermediate risk prostate cancer. How common is that? How is it defined? That would really help. Dr. William Aronson: I would say about 50% of the patients that we diagnose with prostate cancer either have low risk disease or what we call favorable intermediate risk disease. So when the pathologists look at the cancer under the microscope, they assign what's called a Gleason grade. Grade 3 is the slower growing type of prostate cancer, grade 5 is the fastest growing type, and grade 4 is somewhere in between. So a low risk group would be only the grade 3, the slower growing type. And the favorable intermediate risk group would actually be the grade 3+4, which means they mostly see the low risk type in there, but they also see the slightly faster growing type, grade 4. So this is what we typically see. We see these patients on a very regular basis when they're newly diagnosed with prostate cancer. Dr. Shannon Westin: Okay, got it. And then can you walk us through just what the management options are typically for this patient population? Dr. William Aronson: So typically for what we call the low risk group, the patients with a low PSA and only that grade 3 type, slower growing type of prostate cancer, the standard recommendations are active surveillance. So typically, we'll periodically monitor these patients with PSA blood testing and periodically do prostate biopsies depending upon the patient's other medical problems. Dr. Shannon Westin: So I think it would also be really helpful just to understand what your typical management options are for this patient population. Dr. William Aronson: So for patients with low risk prostate cancer, they only have the Gleason Grade 3+3 with a low PSA. The standard practice is observation. And so these men will periodically see them and measure their PSA values. And periodically, they'll undergo prostate biopsy to make sure they're not getting progression of their disease. For men with favorable intermediate risk prostate cancer, that's a little different. In some practices, the patient and the urologist will decide to do active surveillance. In other scenarios, these patients will definitely elect treatment, either with radical prostatectomy or radiation therapy or other treatments that are available. Dr. Shannon Westin: So your manuscript notes that there was a high level of interest in dietary supplements and approaches among patients with prostate cancer that do elect for active surveillance. Prior to the results of CAPFISH-3, did we have any data to support those types of recommendations? Dr. William Aronson: We actually don't have any long term prospective randomized trials that support that recommendation. There have been a number of very interesting epidemiologic studies, for example, suggesting maybe a plant-based diet might be helpful. Or a number of other studies suggesting maybe more tomato-based products like tomato sauces or tomato paste may be helpful. But no prospective longer term randomized trials that were positive. Dr. Shannon Westin: Okay, that makes sense. So what led you all to explore the high omega-3, low omega-6 fatty acid diet in this trial? Dr. William Aronson: After our initial omega-6 studies, we subsequently did some studies where we raised the omega-3 from fish oil and lowered the 6, looking at a more favorable ratio of the omega-3 to omega-6. And once again, we found that in our animal models, there was a significant delay in progression of prostate cancer. That then led us to perform a clinical trial. It was a short term trial in men prior to undergoing radical prostatectomy. And in these men, they were randomly assigned to one of two groups, either a western high fat diet or a low fat diet with fish oil. And we found after just four to six weeks, a significant change in the Ki67 level in their radical prostatectomy tissue. And Ki67 is actually a strong indicator of prostate cancer progression, spread, or even death from prostate cancer. Dr. Shannon Westin: Well, and I think that leads us really nicely into the design of the current study. So why don't you walk us through how CAPFISH-3 was designed. And you've already spoken a little bit about your primary endpoint. Dr. William Aronson: Based on the results of what we saw in the lab and what we saw in our short term clinical trial, we decided to perform a one year trial, a longer term trial in men on active surveillance. And these men were randomly assigned to either a diet with slight reduction in dietary fat, specifically reduction in the omega-6 intake as well as increase in foods with omega-3 and fish oil capsules. The other group, we asked the men to just not take fish oil capsules, but they could eat whatever else they wanted during the course of the study. Men in the diet where we lowered the omega-6 and raised the omega-3, they were seen by a dietitian once a month to really ensure that they were compliant with that intervention, which they were. The other intriguing part of our study, which I think is super important, is the precision that was used when these men underwent prostate biopsy. So, at baseline and at one year, when these men underwent prostate biopsy, they had the same site within the prostate biopsied. That's important because it's not so easy to find the same site within the prostate because of heterogeneity throughout the prostate. And so we were able to obtain that high level of precision as they were in an active surveillance program at UCLA with Dr. Leonard Marks. Dr. Shannon Westin: So we spoke a little bit about what's important about the Ki67 index as your primary endpoint. Can you talk a little bit about what the study found with your intervention? Dr. William Aronson: So we found that the Ki67 index increased by 24% in the control group and decreased by 15% in the low omega-6, high omega-3 group with fish oil capsules. So that ended up resulting in a statistically significant change between the groups favoring the low omega-6, high omega-3 group. Dr. Shannon Westin: And then what were the secondary endpoints that CAPFISH-3 explored? Anything of note that you want to review for the listeners? Dr. William Aronson: So a number of positive secondary endpoints from the trial. Firstly, we saw that the triglyceride levels were lower, which is what can typically be seen with omega-3 intake. We also saw reduced levels of a cytokine, a circulating factor in the bloodstream called ‘macrophage colony stimulating factor'. And that's particularly interesting because there's a certain type of macrophage which is well known to be involved in prostate cancer progression in men with more advanced prostate cancer, and we've been able to inhibit that in our animal models and in our tissue culture studies. And it was especially interesting to see that we did have an effect on this particular cytokine in this prospective randomized trial. We did not see changes in a number of other measures, including Gleason grade or PSA. These are measures that we use in clinical practice. To see an effect on those would have required a longer term and larger study to be performed. Dr. Shannon Westin: That makes sense. I think it's always great to try to get as much of these types of translational data as we can. But sometimes you just have to do what is reasonable and you get what you get. It looks to me like this regimen was fairly well tolerated. Did you obtain any patient reported outcomes or feedback on the trial? Dr. William Aronson: So, there were four patients in the fish oil group that did have some side effects, and we withdrew them from the study. They did have some effects on their upset stomach, and a number of men also had some diarrhea as well. And so for those four patients, we did withdraw them from the study. Dr. Shannon Westin: And then I guess the last question I have is really, what's next for this intervention? Are we ready to move this to the clinic or what do you see as next steps? Dr. William Aronson: Well, this next step that we're working on right now is to better understand exactly what happened in these patients. So we have blood, we have tissue, we're doing genetic studies on these patients. So that's really the first step, in our mind, to better understand what happened before moving to the next step. I'm particularly intrigued about trying this intervention in men with more advanced prostate cancer, specifically because of what we see, this particular diet and how it's affecting the patient's immune system and how that may favorably affect their course of their prostate cancer. Dr. Shannon Westin: Well, great. Well, thank you so much for taking the time to chat with us about such an important clinical trial, and I really appreciate all the work you're doing and hope to get to see you soon. Dr. William Aronson: Well, thanks for having me, Shannon. It's really an exciting finding and I think it's something that clinicians and patients are going to be super interested in. Dr. Shannon Westin: We love straightforward interventions that actually make a difference, so you guys are to be congratulated for that. And I just want to thank all of you for listening. Thanks again, and I hope you enjoyed this episode of JCO After Hours. Be sure to check out our other podcast offerings wherever you get your podcasts. Have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Aronson Disclosures: Stock and Other Ownership Interests Johnson and Johnson Speakers' Bureau Company name: Janssen Oncology, Bayer, Blue Earth Diagnostics, AstraZeneca, Pfizer/Astellas Research Funding: Lantheus Medical Imaging UCLA Health Article Video
Interview with Babette J. A. Verkouteren, MD, PhD, author of Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma
JAMA Dermatology Author Interviews: Covering research on the skin, its diseases, and their treatment
Interview with Babette J. A. Verkouteren, MD, PhD, author of Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. Hosted by Adewole S. Adamson, MD. Related Content: Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular Basal Cell Carcinoma
In this episode, Lillian Erdahl, MD, FACS, is joined by Fatemeh Shojaeian, MD, MPH, from the Johns Hopkins University School of Medicine. They discuss Dr Shojaeian's recent article, “Refractory and Recurrent Idiopathic Granulomatous Mastitis Treatment: Adaptive, Randomized Clinical Trial,” in which the authors found that, for resistant or relapsing patients with idiopathic granulomatous mastitis, combining methotrexate and corticosteroids offers a promising strategy. This integration of disease-modifying antirheumatic drugs with corticosteroids not only reduces the necessity for high steroid doses but also effectively alleviates associated side effects. Disclosure Information: Drs Erdahl and Shojaeian have nothing to disclose. To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more. #JACSOperativeWord
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Dr. Rick Greene discusses with Dr. Heather Neuman and Dr. Alyssa Wiener the results of a randomized trial of topical pain approaches for radiotracer injections for breast cancer sentinel lymph node mapping, as reported in her article, "A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer.”
Dr. Rick Greene discusses with Dr. Heather Neuman and Dr. Alyssa Wiener the results of a randomized trial of topical pain approaches for radiotracer injections for breast cancer sentinel lymph node mapping, as reported in her article, "A Four-Arm Randomized Clinical Trial of Topical Pain Control for Sentinel Node Radiotracer Injections in Patients with Breast Cancer.”
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Discussion by:Guest:Muthiah Vaduganathan, MDCo-Director of the Center for Cardiometabolic Implementation ScienceBrigham and Women's Hospital.2. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening– NEJM 2024. Discussion by:Guest:Mathew Clark, MD Clinical Professor at the Sidney Kimmel medical college of Thomas Jefferson UniversityAssociate Director Family Medicine Residency Program Jefferson Health - Abington3. Mindfulness Meditation vs Escitalopram for Treatment of Anxiety DisordersSecondary Analysis of a Randomized Clinical Trial. JAMA Network Open Discussion by:Guest:Kim Alfonzo, MD Resident– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
This episode of the Ketamine Startup Podcast, comes from a presentation Sam gave at the American College of Emergency Physicians Scientific Assembly on October 1, 2024. Discover the journey of opening a ketamine clinic, the efficacy of IV ketamine for depression, anxiety, PTSD, and chronic pain, and the mechanism behind its success. You will learn about the growing mental health crisis, high burnout rates among emergency physicians, and why ketamine therapy can be a rewarding alternative career path. Sam also shares the emotional and financial realities of running a ketamine clinic, emphasizing the importance of motivation, purpose, and personal fulfillment. Hear powerful testimonials from patients and gain practical advice for starting your own clinic. Don't miss this comprehensive guide filled with scientific studies, real-life experiences, and expert insights.What You'll Learn In This Episode:• Career Transition: Discover how emergency physicians can pivot into running ketamine clinics and find greater autonomy and purpose.• Clinical Evidence: Explore key studies supporting the use of ketamine therapy for depression, anxiety, PTSD, and chronic pain.• Overcoming Challenges: Understand the financial and emotional challenges of running a ketamine clinic and how to stay motivated by focusing on your "why."Episode 22 show notes:00:00 Teaser - The Swimming Pool Dilemma00:35 Introduction01:10 Sam's Journey and Niche in Ketamine Therapy03:12 The Mental Health Crisis05:05 Challenges Faced by Emergency Physicians06:13 Scientific Studies on IV Ketamine Therapy08:45 Ketamine for Anxiety and PTSD10:47 Ketamine for Chronic Pain12:13 How Does Ketamine Work?12:17 Ketamine's Impact on Neurotransmitters13:11 Ketamine and Chronic Stress14:06 Hallucinogenic Effects of Ketamine14:57 Emergency Medicine and Ketamine16:16 Starting a Ketamine Clinic17:19 The Importance of Your 'Why'18:33 Challenges and Rewards of a Ketamine Clinic20:12 Patient Testimonials and Impact21:34 ConclusionThanks for listening
Autonomic dysfunction and tachycardia are strongly linked to poor outcomes in septic shock, contributing to high mortality rates. In the upcoming podcast, we explore whether β-blockade with landiolol for up to 14 days can reduce organ failure, as measured by the Sequential Organ Failure Assessment (SOFA) score, in critically ill patients with tachycardia and septic shock who have been on high-dose norepinephrine for over 24 hours. Dr. Tony Whitehouse, interviewed by two NEXT representatives, discusses the key findings of the STRESS-L Randomized Clinical Trial.
Send us a textLung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial.Vento G, Ventura ML, Pastorino R, van Kaam AH, Carnielli V, Cools F, Dani C, Mosca F, Polglase G, Tagliabue P, Boni L, Cota F, Tana M, Tirone C, Aurilia C, Lio A, Costa S, D'Andrea V, Lucente M, Nigro G, Giordano L, Roma V, Villani PE, Fusco FP, Fasolato V, Colnaghi MR, Matassa PG, Vendettuoli V, Poggi C, Del Vecchio A, Petrillo F, Betta P, Mattia C, Garani G, Solinas A, Gitto E, Salvo V, Gargano G, Balestri E, Sandri F, Mescoli G, Martinelli S, Ilardi L, Ciarmoli E, Di Fabio S, Maranella E, Grassia C, Ausanio G, Rossi V, Motta A, Tina LG, Maiolo K, Nobile S, Messner H, Staffler A, Ferrero F, Stasi I, Pieragostini L, Mondello I, Haass C, Consigli C, Vedovato S, Grison A, Maffei G, Presta G, Perniola R, Vitaliti M, Re MP, De Curtis M, Cardilli V, Lago P, Tormena F, Orfeo L, Gizzi C, Massenzi L, Gazzolo D, Strozzi MCM, Bottino R, Pontiggia F, Berardi A, Guidotti I, Cacace C, Meli V, Quartulli L, Scorrano A, Casati A, Grappone L, Pillow JJ.Lancet Respir Med. 2021 Feb;9(2):159-166. doi: 10.1016/S2213-2600(20)30179-X. Epub 2020 Jul 17.PMID: 32687801 Clinical Trial. Lung Recruitment Before Surfactant Administration in Extremely Preterm Neonates: 2-Year Follow-Up of a Randomized Clinical Trial.Gallini F, De Rose DU, Iuliano R, Romeo DM, Tana M, Paladini A, Fusco FP, Nobile S, Cota F, Tirone C, Aurilia C, Lio A, Esposito A, Costa S, D'Andrea V, Ventura ML, Carnielli V, Dani C, Mosca F, Fumagalli M, Scarpelli G, Giordano L, Fasolato V, Petrillo F, Betta P, Solinas A, Gitto E, Gargano G, Mescoli G, Martinelli S, Di Fabio S, Bernardo I, Tina LG, Staffler A, Stasi I, Mondello I, Scapillati E, Vedovato S, Maffei G, Bove A, Vitaliti M, Terrin G, Lago P, Gizzi C, Strozzi C, Villani PE, Berardi A, Cacace C, Bracaglia G, Pascucci E, Cools F, Pillow JJ, Polglase G, Pastorino R, van Kaam AH, Mercuri E, Orfeo L, Vento G; IN-REC-SUR-E Study Group; Malguzzi S, Rigotti C, Cecchi A, Nigro G, Costabile CD, Roma E, Sindico P, Venafra R, Mattia C, Conversano M, Ballardini E, Manganaro A, Balestri E, Gallo C, Catenazzi P, Astori MG, Maranella E, Grassia C, Maiolo K, Castellano D, Massenzi L, Chiodin E, Gallina MR, Consigli C, Sorrentino E, Bonato S, Mancini M, Perniola R, Giannuzzo S, Tranchina E, Cardilli V, Dito L, Regoli D, Tormena F, Battajon N, Arena R, Allais B, Guidotti I, Roversi F, Meli V, Tulino V, Casati A.JAMA Netw Open. 2024 Sep 3;7(9):e2435347. doi: 10.1001/jamanetworkopen.2024.35347.PMID: 39320892 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos; su anfitriona Maria Flores Cordova, médico residente de pediatría. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comLos artículos que se tratan en el episodio de hoy están listados aquí: van den Akker CHP, Embleton ND, Lapillonne A, et al. Reevaluating the FDA's warning against the use of probiotics in preterm neonates: A societal statement by ESPGHAN and EFCNI. J Pediatr Gastroenterol Nutr. 2024;78(6):1403-1408. doi:10.1002/jpn3.12204Li, J., Zhou, J., Weng, J. et al. Rapidly progressive necrotizing enterocolitis: Risk factors and a predictive model. Pediatr Res (2024). https://doi.org/10.1038/s41390-024-03482-zSalas AA, Gunn E, Carlo WA, et al. Timing of Red Blood Cell Transfusions and Occurrence of Necrotizing Enterocolitis: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024;7(5):e249643. Published 2024 May 1. doi:10.1001/jamanetworkopen.2024.9643Harris L, Lewis S, Vardaman S. Exclusive Human Milk Diets and the Reduction of Necrotizing Enterocolitis. Adv Neonatal Care. 2024;24(5):400-407. doi:10.1097/ANC.0000000000001183 Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos. Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org
In episode 47 we discuss the effectiveness of sublingual and injectable buprenorphine for patients with OUD, with and without fentanyl. Nunes EV, Comer SD, Lofwall MR, Walsh SL, Peterson S, Tiberg F, Hjelmstrom P, Budilovsky-Kelley NR. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Jun 3;7(6):e2417377. We also discuss the AMA's Support of drug decriminalization, and the rise of alcohol-related health problems. New York Times: Oregon Is Recriminalizing Drugs. Here's What Portland Learned Med Page Today: AMA's House of Delegates Says Yes to Drug Decriminalization Stat News: By the numbers: America's alcohol-related health problems are rising fast --- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES. --- Original theme music: composed and performed by Benjamin Kennedy Audio Editing by Michael Bonanno Executive Producer: Dr. Patrick Beeman A podcast from Ars Longa Media --- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice. The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club Instagram: @AddictionMedJC Threads: @AddictionMedJC Twitter/X: @AddictionMedJC YouTube: addictionmedicinejournalclub Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.
En lo último en salud y fitness edición agosto 2024, hablaremos de temas que van desde cómo una simple caminata puede ser tu aliada contra el dolor de espalda, hasta descubrir cómo el ejercicio puede ser tu mejor amigo para dormir mejor si sufres de insomnio. También veremos cómo mantener tus huesos fuertes mientras pierdes peso, y platicaremos sobre alternativas naturales para manejar la ansiedad y la depresión. Y ojo, porque hasta el aire que respiras en casa podría estar afectando tu estado de ánimo. Vamos a desmenuzar estos estudios recientes, ver qué nos dicen los datos y, lo más importante, cómo podemos aplicar esta información en nuestra vida diaria. Atajos del Episodio 01:40 - Camina a tu ritmo: Un plan para evitar y demorar el dolor de espalda1 06:39 - Protegiendo los huesos mientras pierdes peso: el papel del ejercicio2 11:36 - El ejercicio mejora notablemente el sueño en adultos con insomnio3 14:51 - Azafrán: Una alternativa segura y eficaz a los antidepresivos4 17:32 - Contaminación del aire interior y su relación con el riesgo de depresión5 Referencias: 1. Pocovi, N. C., Lin, C. W. C., French, S. D. & Graham…, P. L. Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia …. The Lancet (2024). 2. Jensen, S. B. K., Sørensen, V. & Sandsdal…, R. M. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial. JAMA network … (2024). 3. Riedel, A., Benz, F., Deibert, P., Barsch, F. & Frase…, L. The effect of physical exercise interventions on insomnia: a systematic review and meta-analysis. Sleep Medicine … (2024). 4. Shafiee, A., Jafarabady, K. & Seighali…, N. Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials. Nutrition … (2024). 5. Zhang, X. et al. Association between indoor air pollution and depression: a systematic review and meta-analysis of cohort studies. BMJ open (2024).
Sometimes health professional education can be embarrassing. Despite the maturity of the field, there are occasions when a study, such as the one in Jon's paper selection this week, can highlight shared assumptions among clinician educators. So, what is the most effective way to teach a technical skill? The KeyLIME team is here to help you figure it out! Authors: Rossettini G, Rondoni A, Palese A, Cecchetto S, Vicentini M, Bettale F, Furri L, Testa M. Publication details: Effective teaching of manual skills to physiotherapy students. A Randomized Clinical Trial. Medical Education. 2017. August. [ePub ahead of print]
Send us a Text Message.Diazoxide for Severe or Recurrent Neonatal Hypoglycemia: A Randomized Clinical Trial.Laing D, Walsh EPG, Alsweiler JM, Hanning SM, Meyer MP, Ardern J, Cutfield WS, Rogers J, Gamble GD, Chase JG, Harding JE, McKinlay CJD.JAMA Netw Open. 2024 Jun 3;7(6):e2415764. doi: 10.1001/jamanetworkopen.2024.15764.PMID: 38869900 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
Did you know that 13% of trauma patients who go home with an opioid prescription will develop opioid dependence? Multimodal pain regimens not only reduce opioid consumption, but also improve pain control. On this episode of the BIG T TRAUMA series, we explore a multimodal approach to pain management...and tackle some surgical dogma along the way. Hosts: Patrick Georgoff, MD, Trauma Surgeon, Duke University, @georgoff Teddy Puzio, MD, Trauma Surgeon, University of Texas Houston Gabby Hatton, MD, Trauma Surgery fellow, University of Texas Houston References: 1. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open 2020: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767637 2. Traumatic injuries and persistent opioid use in the USA: findings from a nationally representative survey. Injury Prevention 2017: https://pubmed.ncbi.nlm.nih.gov/27597400/ 3. Ketamine For Acute Pain After Trauma (KAPT): A Pragmatic, Randomized Clinical Trial. J Trauma 2024: https://pubmed.ncbi.nlm.nih.gov/38689402/ 4. EAST PMG: Efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of acute pain after orthopedic trauma (2023): https://www.east.org/education-resources/practice-management-guidelines/details/efficacy-and-safety-of-nonsteroidal-antiinflammatory-drugs-nsaids-for-the-treatment-of-acute-pain-af 5. Systematic Review and Meta-Analysis of the Association Between Non-Steroidal Anti-Inflammatory Drugs and Operative Bleeding in the Perioperative Period. JACS 2021: https://pubmed.ncbi.nlm.nih.gov/33515678/ 6. Is the use of nonsteroidal anti-inflammatories after bowel anastomosis in trauma safe? J Trauma 2023: https://pubmed.ncbi.nlm.nih.gov/36728125/ 7. University of Texas at Houston Multimodal Pain Guideline: https://med.uth.edu/surgery/acute-trauma-pain-multimodal-therapy/ 8. ACS TRAUMA QUALITY PROGRAMS BEST PRACTICES GUIDELINES FOR ACUTE PAIN MANAGEMENT IN TRAUMA PATIENTS: https://www.facs.org/media/exob3dwk/acute_pain_guidelines.pdf Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
On Episode 42 of the Stroke Alert Podcast, host Dr. Negar Asdaghi highlights two articles from the July 2024 issue of Stroke: “Dual Antiplatelet Therapy After Embolic Stroke of Undetermined Source: A Subgroup Analysis of the CHANCE-2 Trial” and “Risk of Stroke in Women Using Levonorgestrel-Releasing Intrauterine Device for Contraception.” She also interviews Dr. Manabu Inoue about his article “Expanding the Treatable Imaging Profile in Patients With Large Ischemic Stroke: Subanalysis From a Randomized Clinical Trial.”
Raphael e Marcela convidam novamente Nathalie Santana para falar sobre tratamento do hipertiroidismo em 4 clinicagens: como escolher o melhor tratamento? como controlar os sintomas? como prescrever drogas antitireoidianas? como monitorar o paciente? Use o cupom TDC2024 para assinar o HITT do Medcof e ganhe um cupom de 6 meses gratuitos do Guia TdC! https://hiit.grupomedcof.com.br Referências: 1. Azizi, F et al. “Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.” European journal of endocrinology vol. 152,5 (2005): 695-701. doi:10.1530/eje.1.01904 2. Villagelin, Danilo et al. “Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment.” Thyroid : official journal of the American Thyroid Association vol. 25,12 (2015): 1282-90. doi:10.1089/thy.2015.0195 3. Kahaly, George J et al. “2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.” European thyroid journal vol. 7,4 (2018): 167-186. doi:10.1159/000490384 4. Villagelin, Danilo et al. “A 2023 International Survey of Clinical Practice Patterns in the Management of Graves' Disease: A Decade of Change.” The Journal of clinical endocrinology and metabolism, dgae222. 5 Apr. 2024, doi:10.1210/clinem/dgae222 5. Ross, Douglas S et al. “2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.” Thyroid : official journal of the American Thyroid Association vol. 26,10 (2016): 1343-1421. doi:10.1089/thy.2016.0229 6. Shalaby M, Hadedeya D, Toraih EA, et al. Predictive factors of radioiodine therapy failure in Graves' Disease: A meta-analysis. Am J Surg. 2022;223(2):287-296. doi:10.1016/j.amjsurg.2021.03.068 7. Carella, C et al. “Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.” Thyroid : official journal of the American Thyroid Association vol. 16,3 (2006): 295-302. doi:10.1089/thy.2006.16.295 8. Struja T, Kaeslin M, Boesiger F, et al. External validation of the GREAT score to predict relapse risk in Graves' disease: results from a multicenter, retrospective study with 741 patients. Eur J Endocrinol. 2017;176(4):413-419. doi:10.1530/EJE-16-0986 9. Park SY, Kim BH, Kim M, et al. The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea. Endocrine. 2021;74(1):120-127. doi:10.1007/s12020-021-02725-x 10. Azizi F, Amouzegar A, Tohidi M, et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Thyroid. 2019;29(9):1192-1200. doi:10.1089/thy.2019.0180 11. Chaker L, Cooper DS, Walsh JP, Peeters RP. Hyperthyroidism. Lancet. 2024;403(10428):768-780. doi:10.1016/S0140-6736(23)02016-0 12. Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472-1483. doi:10.1001/jama.2023.19052 13. https://www.tadeclinicagem.com.br/guia/146/tempestade-tireotoxica/
Hosts Angela Huttner & Erin McCreary welcome Prof. David Paterson (Singapore) and Prof. Josh Davis (Newcastle, Australia) to discuss the design and results of the BLING-3 trial, which compared continuous infusion of beta-lactam antibiotics to standard intermittent dosing in 7000 critically ill patients across 104 intensive-care units. In unadjusted analyses, the trial did not show a statistically significant mortality benefit with continuous infusion. Yet in prespecified adjusted analyses, there was a statistically significant reduction in mortality, and a meta-analysis of randomized trials published simultaneously with the BLING-3 trial showed the same. As the two ID doctors on the BLING team, Profs. Paterson and Davis offer context and insights into what these results mean and how they might affect your clinical practice. Episode peer-reviewed by Dr. Mia Lidén of Charité – Universitätsmedizin Berlin. LiteratureBLING-1: Dulhunty et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013 Jan;56(2):236-44. DOI: 10.1093/cid/cis856BLING-2: Dulhunty et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1298-305. DOI: 10.1164/rccm.201505-0857OCBLING-3: Dulhunty et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. JAMA. 2024 Jun 12:e249779.DOI: 10.1001/jama.2024.9779Meta-analysis: Abdul-Aziz et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis. JAMA. 2024 Jun 12:e249803. DOI: 10.1001/jama.2024.9803
Journal of the American Academy of Child and Adolescent Psychiatry
JAACAP June 2024: Contributing Editor Dr. Jesse Hinckley interviews Dr. James D. Lock about a study investigating the addition of 3 sessions of intensive parental coaching intervention to family-based treatment among youth with anorexia who did not gain adequate weight early in treatment, a predictor of recovery by the end of treatment.
Send us a Text Message.Timing of Red Blood Cell Transfusions and Occurrence of Necrotizing Enterocolitis: A Secondary Analysis of a Randomized Clinical Trial. Salas AA, Gunn E, Carlo WA, Bell EF, Das A, Josephson CD, Patel RM, Tan S, Kirpalani H; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network. JAMA Netw Open. 2024 May 1;7(5):e249643. doi: 10.1001/jamanetworkopen.2024.9643.PMID: 38700862 As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
In this special series on obesity, our host, Dr. Neil Skolnik, discusses the obesity epidemic with some of the foremost experts in the world. In Part 4 of the series, Dr. Skolnik is joined by Drs. Deborah Horn and Robert Kushner. Together they discuss challenges, and potential solutions, in obesity management. The Focus on Obesity series is a collaborative project of the American Diabetes Association and the American Academy of Family Physicians. The entire program will comprise a total of seven episodes: four episodes of Diabetes Core Update, which will cover topics of interest for family physicians, primary care clinicians, and other health care professionals; as well as three episodes of its sister podcast, Diabetes Day by Day, which will be tailored for people with overweight or obesity and their caregivers. The combined seven-episode program will be released between February and June 2024 and can be freely accessed at https://diabetesjournals.org/journals/pages/podcasts_obesity. Funding support for the “Focus on Obesity” series is jointly provided by Lilly and Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Deborah B. Horn, DO, MPH, Medical Director for the UT Center of Obesity Medicine and Metabolic Performance; Fellowship Program Director, Allison Family Foundation Fellowship in Clinical Obesity Medicine and Metabolism, McGovern Medical School Robert Kushner, MD, Professor of Medicine (Endocrinology) and Medical Education Feinburg School of Medicine at Northwestern University and Medical Director of the Wellness Institute at Northwestern Memorial Hospital in Chicago Selected references: STEP – 4 Trial - Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021; 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224 SURMOUNT-4 Trial - Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
Welcome back Rounds Table Listeners!In this throwback episode, Drs. Mike and John Fralick discuss two papers exploring early metformin in Gestational Diabetes and tirzepatide versus short-acting insulin when added to basal insulin regimens in patients with Type II Diabetes. Early Metformin in Gestational Diabetes: A Randomized Clinical Trial (0:00 – 9:28).Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial (9:28 – 19:00).And for the Good Stuff:N.B. woman meets her Mississippi bone marrow donor a decade after donation (19:00 – 19:45).The Intern at Work Podcast (19:45 – 21:10).Questions? Comments? Feedback? We'd love to hear from you! @roundstable
Host Dr. Arun Aneja interviews paper author Dr. Antti Launonen. This paper was presented at the 2023 OTA Annual Meeting. This paper was presented at the 2023 OTA Annual Meeting, and the published article can be found at the link: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004308 . To see the abstract, download the free ConveyMED app: Apple Store or Google Play For additional educational resources visit https://ota.org/.
In this second of a two part podcast special Iain and Simon go through twenty of the top papers from the last year or so, as presented by Simon at the Big Sick Conference in Zermatt earlier this year. All the details and more discussion can be found on the blog site. In Part 2 they discuss papers about major haemorrhage, trauma, cardiac arrest and more. In Part 1 they discuss all things airway, including where we should be intubating patients needing immediate haemorrhage control. VL vs DL, the effect of blade size on intubation success, whether small adult ventilation bags are better than larger versions, intubating comatose poisoned patients, and more. Papers Jansen JO et al. Emergency Department Resuscitative Endovascular Balloon Occlusion of the Aorta in Trauma Patients With Exsanguinating Hemorrhage: The UK-REBOA Randomized Clinical Trial. JAMA. 2023 Nov 21;330(19):1862-1871. doi: 10.1001/jama.2023.20850. PMID: 37824132; PMCID: PMC10570916. Davenport R et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA. 2023 Nov 21;330(19):1882-1891. doi: 10.1001/jama.2023.21019. PMID: 37824155; PMCID: PMC10570921. PATCH-Trauma Investigators and the ANZICS Clinical Trials Group; Prehospital Tranexamic Acid for Severe Trauma. N Engl J Med. 2023 Jul 13;389(2):127-136. doi: 10.1056/NEJMoa2215457. Epub 2023 Jun 14. PMID: 37314244. Shepherd JM et al Safety and efficacy of artesunate treatment in severely injured patients with traumatic hemorrhage. The TOP-ART randomized clinical trial. Intensive Care Med. 2023 Aug;49(8):922-933. doi: 10.1007/s00134-023-07135-3. Epub 2023 Jul 20. PMID: 37470832; PMCID: PMC10425486. Bouzat P et al. Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial. JAMA. 2023 Apr 25;329(16):1367-1375. doi: 10.1001/jama.2023.4080. PMID: 36942533; PMCID: PMC10031505. Torres CM, Kent A, Scantling D, Joseph B, Haut ER, Sakran JV. Association of Whole Blood With Survival Among Patients Presenting With Severe Hemorrhage in US and Canadian Adult Civilian Trauma Centers. JAMA Surg. 2023 May 1;158(5):532-540. doi: 10.1001/jamasurg.2022.6978. Erratum in: JAMA Surg. 2023 Apr 5;: PMID: 36652255; PMCID: PMC9857728. Marsden MER, Kellett S, Bagga R, Wohlgemut JM, Lyon RL, Perkins ZB, Gillies K, Tai NR. Understanding pre-hospital blood transfusion decision-making for injured patients: an interview study. Emerg Med J. 2023 Nov;40(11):777-784. doi: 10.1136/emermed-2023-213086. Epub 2023 Sep 13. PMID: 37704359; PMCID: PMC10646861. Wohlgemut JM, Pisirir E, Stoner RS, Kyrimi E, Christian M, Hurst T, Marsh W, Perkins ZB, Tai NRM. Identification of major hemorrhage in trauma patients in the prehospital setting: diagnostic accuracy and impact on outcome. Trauma Surg Acute Care Open. 2024 Jan 12;9(1):e001214. doi: 10.1136/tsaco-2023-001214. PMID: 38274019; PMCID: PMC10806521. Cheskes S, Verbeek PR, Drennan IR, McLeod SL, Turner L, Pinto R, Feldman M, Davis M, Vaillancourt C, Morrison LJ, Dorian P, Scales DC. Defibrillation Strategies for Refractory Ventricular Fibrillation. N Engl J Med. 2022 Nov 24;387(21):1947-1956. doi: 10.1056/NEJMoa2207304. Epub 2022 Nov 6. PMID: 36342151. Siddiqua N, Mathew R, Sahu AK, Jamshed N, Bhaskararayuni J, Aggarwal P, Kumar A, Khan MA. High-dose versus low-dose intravenous nitroglycerine for sympathetic crashing acute pulmonary edema: a randomised controlled trial. Emerg Med J. 2024 Jan 22;41(2):96-102. doi: 10.1136/emermed-2023-213285. PMID: 38050078. Wilkinson-Stokes M, Betson J, Sawyer S. Adverse events from nitrate administration during right ventricular myocardial infarction: a systematic review and meta-analysis. Emerg Med J. 2023 Feb;40(2):108-113. doi: 10.1136/emermed-2021-212294. Epub 2022 Sep 30. PMID: 36180168. Patterson T, Perkins GD, Perkins A, Clayton T, Evans R, Dodd M, Robertson S, Wilson K, Mellett-Smith A, Fothergill RT, McCrone P, Dalby M, MacCarthy P, Firoozi S, Malik I, Rakhit R, Jain A, Nolan JP, Redwood SR; ARREST trial collaborators. Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial. Lancet. 2023 Oct 14;402(10410):1329-1337. doi: 10.1016/S0140-6736(23)01351-X. Epub 2023 Aug 27. PMID: 37647928. Issa EC, Ware PJ, Bitange P, Cooper GJ, Galea T, Bengiamin DI, Young TP. The “Syringe Hickey”: An Alternative Skin Marking Method for Lumbar Puncture. J Emerg Med. 2023 Mar;64(3):400-404. doi: 10.1016/j.jemermed.2023.01.013. PMID: 37019501.
In this special series on obesity, our host, Dr. Neil Skolnik, discusses the obesity epidemic with some of the foremost experts in the world. In Part 2 of the series, Dr. Skolnik is joined by Drs. Deborah Horn, Thomas Wadden, and Donna Ryan. Together, they discuss, in detail, approaches to obesity including lifestyle, medications and bariatric surgery. The Focus on Obesity series is a collaborative project of the American Diabetes Association and the American Academy of Family Physicians. The entire program will comprise a total of seven episodes: four episodes of Diabetes Core Update, which will cover topics of interest for family physicians, primary care clinicians, and other health care professionals; as well as three episodes of its sister podcast, Diabetes Day by Day, which will be tailored for people with overweight or obesity and their caregivers. The combined seven-episode program will be released between February and June 2024 and can be freely accessed at https://diabetesjournals.org/journals/pages/podcasts_obesity. Funding support for the “Focus on Obesity” series is jointly provided by Lilly and Novo Nordisk. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Thomas Wadden PhD, is a Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. He is the former director of the Center for Weight and Eating Disorders at Penn. Donna Ryan, MD Professor emeritus at the Pennington Biomedical Research Center in Baton Rouge, Louisiana. Deborah B. Horn, DO, MPH, Medical Director for the UT Center of Obesity Medicine and Metabolic Performance; Fellowship Program Director, Allison Family Foundation Fellowship in Clinical Obesity Medicine and Metabolism, McGovern Medical School Selected references: STEP-1 Trial (Semaglutide) – Wilding J, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021; 384(11), 989-1002. DOI: 10.1056/NEJMoa2032183 SURMOUNT-1 Trial (Tirzepatide) - Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et. al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine. 2022; 387(3), 205-216. DOI: 10.1056/NEJMoa2206038 STEP – 4 Trial - Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021; 325(14), 1414-1425. DOI: 10.1001/jama.2021.3224 SURMOUNT-4 Trial - Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945 Diabetes Prevention Program Trial: Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393– 403 Look Ahead Trial: Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.
Dr. Drew Rothenberg (Duke University, Durham, NC) joins AJP Audio to discuss the long term, intergenerational impacts of the Fast Track program, and whether the mental health intervention lead to lasting improvements in mental health, including in the participants own children. 00:49 Rothenberg interview 04:36 A null result? 07:13 At risk children from high risk neighborhoods 08:00 Limitations 09:17 Demand for childhood mental health services and clinical implications 11:10 Further research 13:59 Kalin interview 14:12 Rothenberg et al. 16:12 Haller et al. 18:49 Poirot et al. 20:55 Ainsworth et al. 23:20 Rosenqvist et al. Transcript Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it. Subscribe to the podcast here. Listen to other podcasts produced by the American Psychiatric Association. Browse articles online. How authors may submit their work. Follow the journals of APA Publishing on Twitter. E-mail us at ajp@psych.org
We have a panel discussion with authors Albert Wiegman and Frederick Raal and Editorialist Raul Santos as they discuss the original research articles "Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia" and "Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial." For the episode transcript, visit: https://www.ahajournals.org/do/110.1161/podcast.20240129.812328
Unlock the secrets to a pain-free life - recent research reveals that retraining your brain is the key to saying goodbye to chronic back pain without surgery. But is life without pain possible? Even if you have an x-ray or MRI that says the only fix is surgical? Here's a revelation: MRI studies on people without back pain consistently reveal a significant percentage with disc issues but zero pain. This challenges the idea that disc issues are always correlated with pain. And I know this goes against what most of us have been told about back pain — which is precisely why I recorded this episode. There is an increasing amount of data and research that has found decreases in pain with mindfulness-based stress reduction techniques but it seems that information has yet to reach orthopedic surgeons in practice. So if you believe that life without pain is possible, but you're not quite sure how to get there — today's episode is for you!
Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field. This issue will review: 1. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial 2. Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use 3. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease vs usual care in adults with type 2 diabetes or chronic obstructive pulmonary 4. Low-Dose Anti-thymocyte Globulin: Treating Stage 2 Type 1 Diabetes 5. Assessment of Glycemic Control by CGM, Hemoglobin A1c, Fructosamine and Glycated Albumin in Patients with End-Stage Kidney Disease and Burnt-Out Diabetes For more information about each of ADA's science and medical journals, please visitwww.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health
You might have heard the buzz around berberine, often referred to as “nature's Ozempic”. Berberine is a powerhouse for many things, from reducing inflammation to regulating blood sugar levels. Tune in to hear which benefits the science supports (and the surprising ones it doesn't) and get a simple dosing guide. And if you have any additional questions you would like answered in the future, let me know in the comments! Watch/Read Next… Diets Debunked: The Noom Program: https://drruscio.com/noom-debunked/ Diets Debunked: Weight Watchers: https://drruscio.com/weight-watchers/ Genetic Testing for Weight Loss Isn't Worth it. Here's what is: https://drruscio.com/genetic-testing-for-weight-loss/ How to Heal Your Gut Naturally: https://drruscio.com/how-to-heal-your-gut-naturally/ Timestamps 00:00 Intro 01:00 What is berberine? 01:37 Weight loss 02:34 Cholesterol 05:52 Blood sugar 08:47 Gut health 11:15 SIBO 12:53 Berberine dosing guide Featured Studies Biological properties and clinical applications of berberine: https://pubmed.ncbi.nlm.nih.gov/32335802/ Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders: https://pubmed.ncbi.nlm.nih.gov/30186157/ The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials: https://pubmed.ncbi.nlm.nih.gov/31915452/ The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials: https://pubmed.ncbi.nlm.nih.gov/32690176/ The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis: https://www.sciencedirect.com/science/article/abs/pii/S2213434423000361 Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice: https://pubmed.ncbi.nlm.nih.gov/31666640/ Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption: https://pubmed.ncbi.nlm.nih.gov/25002181/ Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/36941490/ Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials: https://pubmed.ncbi.nlm.nih.gov/31094214/ The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/34956436/ Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/37598753/ Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials: https://pubmed.ncbi.nlm.nih.gov/37675930/ Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice: https://pubmed.ncbi.nlm.nih.gov/31306972/ Berberine Enhances Intestinal Mucosal Barrier Function by Promoting Vitamin D Receptor Activity: https://pubmed.ncbi.nlm.nih.gov/37046128/ Berberine influences multiple diseases by modifying gut microbiota: https://pubmed.ncbi.nlm.nih.gov/37599699/ Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner: https://pubmed.ncbi.nlm.nih.gov/26700862/ A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: https://pubmed.ncbi.nlm.nih.gov/26400188/ Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34509605/ Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study): https://pubmed.ncbi.nlm.nih.gov/36873985/ Berberine and health outcomes: An umbrella review: https://pubmed.ncbi.nlm.nih.gov/36999891/ Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats: https://pubmed.ncbi.nlm.nih.gov/21637946/ Efficacy of berberine in patients with type 2 diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/18442638/ Get the Latest Updates Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/ Pinterest - https://www.pinterest.com/drmichaelrusciodc DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.
Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD. Related Content: Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
Host Dr. Malcolm DeBaun interviews paper author Dr. Brandon Yuan. This paper was presented at the 2023 OTA Annual Meeting. To view the abstract while listening, download the free ConveyMED App: Apple Store click here Google Play click here. For additional educational resources visit https://ota.org/
Welcome BACK to the Balanced Bodies Blueprint! In this episode, hosts Vinny Russo and Dr. Eryn Stansfield dismantle diet dogma. Unravel misconceptions about fats, carbs, and calories, and gain insights into a holistic approach to nutrition. Insights: *Carbs and Fats Unveiled: Understand the truth about dietary fats and carbs – they're not the enemy, and challenge the belief that carbs hinder weight loss. *Low-Carb Reality: Explore the consequences of extreme low-carb diets. Carbs are crucial for energy. *Genetic Weight Loss: Dive into a study on weight loss in high-carb and high-fat diets based on individual genotypes. *Calorie Hierarchy: Vinny emphasizes the hierarchy of nutrition, focusing on calorie intake, protein, and exercise. *Calorie Calculators Exposed: Generic calculators don't consider individual goals. Vinny recommends personalized approaches. *AI in Nutrition: While AI can assist, the human touch is irreplaceable in coaching. *Glycemic Index vs. Load: Vinny favors glycemic load for a comprehensive understanding of carbs' impact on blood sugar. Tune in for a paradigm shift in your health journey. Leave a 5-star review, share on social media, and join the conversation! If You're Ready to take the next step? Sign up to work with Balanced Bodies for individual coaching and support. Your health and fitness goals are within reach. Have questions or feedback? Leave a comment, visit our website, or connect with us on social media. We'd love to hear from you. Coach VinnyEmail: vinny@balancedbodies.ioInstagram: vinnyrusso_balancedbodiesFacebook: Vinny Russo Dr. ErynEmail: dr.eryn@balancedbodies.ioInstagram: dr.eryn_balancedbodiesFacebook: Eryn Stansfield LEGION 20% OFF CODEGo to https://legionathletics.com/ and use the code RUSSO for 20% off your order! Sources Mentioned in this Episode: Höchsmann, C., Yang, S., Ordovás, J.M. et al. The Personalized Nutrition Study (POINTS): evaluation of a genetically informed weight loss approach, a Randomized Clinical Trial. Nat Commun 14, 6321 (2023). https://doi.org/10.1038/s41467-023-41969-1
Impella, digital health, low-value processes, are tricuspid valve interventions with pacing leads are the topics Dr. John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Impella Class I Recall FDA Class I Recall for Some Abiomed Impella Heart Pumps https://www.medscape.com/viewarticle/992845 - A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.112.098194 - Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction https://doi.org/10.1016/j.jacc.2016.10.022 https://www.sciencedirect.com/science/article/pii/S0735109716367675?via%3Dihub - The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.119.044007 - Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock https://jamanetwork.com/journals/jama/fullarticle/2761003 - Danish Cardiogenic Shock Trial (DanShock) https://clinicaltrials.gov/ct2/show/NCT01633502 II. Wearable Devices - Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805753 doi:10.1001/jamanetworkopen.2023.16634 - Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01698-6/fulltext - Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362 III. The Cost of Quality Measures - The Volume and Cost of Quality Metric Reporting https://jamanetwork.com/journals/jama/fullarticle/2805705 - Goodhart's law https://en.wikipedia.org/wiki/Goodhart%27s_law IV. Tricuspid Valve Interventions and Pacing Leads Leadless Dual-Chamber Pacemaker Clears Early Safety, Performance Hurdles https://www.medscape.com/viewarticle/992464 - Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience https://www.jacc.org/doi/10.1016/j.jcin.2022.01.280 - Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Comparison of Transvenous versus Subcutaneous Leads https://eppro01.ativ.me/src/EventPilot/php/express/web/planner.php?id=HRS23&utm_source=heartrhythm&utm_medium=nav-button&utm_campaign=hr23-webtracking - Management and Outcomes of Transvenous Pacing Leads in Patients Undergoing Transcatheter Tricuspid Valve Replacement https://www.jacc.org/doi/10.1016/j.jcin.2020.04.054 - TRILUMINATE trial -- Transcatheter Repair for Patients with Tricuspid Regurgitation https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net
© 2020-2025 Ivy Podcast Discovery LLC
